Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. It is a condition characterized by the overproduction of red blood ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

The investigators in a recent study found that prior thrombotic events and leukocytosis were linked to subsequent thrombotic events in general, and prior arterial events and hyperlipidemia were linked ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

Acute Myocardial Infarction (MI) managed with thrombolysis in a Polycythemia Vera (PV) patient shows that early diagnostic ...

LIVER tumors, usually hepatomas, are relatively frequent in cases of hepatic cirrhosis, occurring in approximately 3 or 4 per cent of patients with alcoholic cirrhosis and in a somewhat higher ...

The SANRECO study investigates divesiran for polycythemia vera, focusing on regulating iron metabolism to control red blood cell production. Current PV treatments include therapeutic phlebotomy, ...

December 8, 2012 — Atlanta, GA — Maintaining a lower hematocrit (HCT) can help lower the risk for cardiovascular (CV) death in patients with polycythemia vera, according to the results of a new study.

Polycythemia vera is the ultimate phenotypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to which this mutation influences the behavior of the involved CD34+ ...

Background A 16-year-old white male with a history of obstructive uropathy presented to a pediatric outpatient clinic with a first syncope. At presentation, he had a hemoglobin level of 220 g/l, a ...